Recent studies have reported that pancreatic ductal adenocarcinoma (PDA) patients with KRAS G12R mutations have longer overall survival compared to patients without G12R mutation, but this advantage is offset by concomitant PI3K alterations [8]. This evidence concerns the gene PIK3CA and Patent ductus arteriosus.